Science & Technology

Overview

NeoVista is investigating the safety and efficacy of a potential new treatment for wet age-related macular degeneration (AMD)—epimacular beta radiation therapy. This unique therapy is currently being utilized in a pivotal Phase III study to support our application for marketing approval in the United States.

In this section you can learn about beta radiation and its uses in ophthalmology, and how the NeoVista approach may offer new hope to patients with wet AMD.

Learn more about the NeoVista procedure.

Learn more about beta radiation.